New drug cocktail aims to tackle tough pancreatic cancer

NCT ID NCT06646055

Ongoing Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two experimental drugs, AK112 and cadonilimab, combined with standard chemotherapy as a first treatment for people with metastatic pancreatic cancer. About 110 participants will receive the combination to see if it is safe and helps shrink tumors. The goal is to find a better option for this hard-to-treat cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK112, cadonilimab, nab-paclitaxel, gemcitabine
What this could lead to: If successful, this combination could offer a new first-line treatment option for metastatic pancreatic cancer, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 110 participants, so results may not apply broadly. The added drugs may increase side effects, and the treatment may not work better than standard chemotherapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.